CoChat

Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy

Alfano, Lindsay N., Charleston, Jay S., Connolly, Anne M., Cripe, Linda, Donoghue, Cas, Dracker, Robert, Dworzak, Johannes, Eliopoulos, Helen, Frank, Diane E., Lewis, Sarah, Lucas, Karin, Lynch, Jessie, Milici, A. J., Flynt, Amy, Naughton, Emily, Rodino-Klapac, Louise R., Sahenk, Zarife, Schnell, Frederick J., Young, G. David, Mendell, Jerry R., Lowes, Linda P. · 2019 · Medicine
Cited by 79

The DOI matches its Crossref record.

Abstract

This analysis aims to describe the outcomes of two nonambulatory patients with Duchenne muscular dystrophy (DMD) who participated in two clinical studies. The two consecutive trials of eteplirsen (studies 201 and 202) were conducted in patients with DMD (N = 12) and confirmed genetic mutations amenable to exon 51 skipping. In study 201, 12 patients were randomized to receive once-weekly, double-blind intravenous infusions of eteplirsen 30 or 50 mg/kg or placebo for 24 weeks; patients then received open-label eteplirsen during weeks 25 through 28. All 12 patients continued onto open-label extension study 202 and received long-term treatment with eteplirsen. We compared cardiac, pulmonary, and upper limb function and dystrophin production in the nonambulatory twin patients versus the 10 ambulatory patients through 240 combined treatment weeks. Ten study patients remained ambulatory through both studies, while the identical twin patients both experienced early, rapid loss of ambulation. The twin patients had greater disease severity at baseline (6-minute walk test [6MWT], 330 and 256 m) versus the other patients (n = 10; 6MWT range, 341–418 m). They maintained cardiac and upper limb function through combined week 240, with outcomes similar to those of the patients who remained ambulatory. Dystrophin production was confirmed following eteplirsen treatment. Despite the loss of ambulation, other markers of disease progression remained relatively stable in the eteplirsen-treated twin patients and were similar to those of the ambulatory patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000015858

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 29

  1. Kole, 2015, Exon skipping therapy for Duchenne muscular dystrophy, Adv Drug Deliv Rev, 87, 104, 10.1016/j.addr.2015.05.008 · DOI · Paper page
  2. Mendell, 2013, Eteplirsen for the treatment of Duchenne muscular dystrophy, Ann Neurol, 74, 637, 10.1002/ana.23982 · DOI · Paper page
  3. McNeil, 2010, Duchenne muscular dystrophy: drug development and regulatory considerations, Muscle Nerve, 41, 740, 10.1002/mus.21623 · DOI
  4. Bushby, 2010, Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care, Lancet Neurol, 9, 177, 10.1016/S1474-4422(09)70272-8 · DOI · Paper page
  5. Bushby, 2010, Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management, Lancet Neurol, 9, 77, 10.1016/S1474-4422(09)70271-6 · DOI · Paper page
  6. Fayssoil, 2010, Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics, Heart Fail Rev, 15, 103, 10.1007/s10741-009-9156-8 · DOI
  7. Voit, 2014, Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study, Lancet Neurol, 13, 987, 10.1016/S1474-4422(14)70195-4 · DOI · Paper page
  8. Bushby, 2014, Ataluren treatment of patients with nonsense mutation dystrophinopathy, Muscle Nerve, 50, 477, 10.1002/mus.24332 · DOI · Paper page
  9. Mendell, 2016, Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy, Ann Neurol, 79, 257, 10.1002/ana.24555 · DOI · Paper page
  10. Charleston, 2018, Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production, Neurology, 90, e2146, 10.1212/WNL.0000000000005680 · DOI · Paper page
  11. Poole, 2005, Measuring dexterity in children using the Nine-hole Peg Test, J Hand Ther, 18, 348, 10.1197/j.jht.2005.04.003 · DOI · Paper page
  12. Pane, 2014, Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes, PLoS One, 9, e108205, 10.1371/journal.pone.0108205 · DOI
  13. Mazzone, 2011, Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study, Neurology, 77, 250, 10.1212/WNL.0b013e318225ab2e · DOI · Paper page
  14. LoMauro, 2015, Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options, Ther Clin Risk Manag, 11, 1475
  15. Roberto, 2011, The natural history of cardiac and pulmonary function decline in patients with Duchenne muscular dystrophy, Spine, 36, E1009, 10.1097/BRS.0b013e3181fea1ed · doi:10.1097/brs.0b013e3181fea1ed
  16. Mayer, 2015, Characterization of pulmonary function in Duchenne muscular dystrophy, Pediatr Pulmonol, 50, 487, 10.1002/ppul.23172 · DOI
  17. Connolly, 2015, Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy, Muscle Nerve, 51, 522, 10.1002/mus.24346 · DOI
  18. Mayhew, 2007, Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy, Muscle Nerve, 35, 36, 10.1002/mus.20654 · DOI
  19. Mayer, 2017, Advances in pulmonary care in Duchenne muscular dystrophy, US Neurology, 13, 35
  20. Finder, 2017, Pulmonary endpoints in Duchenne muscular dystrophy. A workshop summary, Am J Respir Crit Care Med, 196, 512, 10.1164/rccm.201703-0507WS · DOI
  21. Connolly, 2016, Clinical trial readiness in non-ambulatory boys and men with Duchenne muscular dystrophy: MDA-DMD network follow-up, Muscle Nerve, 54, 681, 10.1002/mus.25089 · doi:10.1002/mus.25089
  22. Duboc, 2005, Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy, J Am Coll Cardiol, 45, 855, 10.1016/j.jacc.2004.09.078 · DOI
  23. Tandon, 2015, Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy, J Am Heart Assoc, 4, e001338, 10.1161/JAHA.114.001338 · doi:10.1161/jaha.114.001338
  24. Schram, 2013, All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy, J Am Coll Cardiol, 61, 948, 10.1016/j.jacc.2012.12.008 · DOI · Paper page
  25. Birnkrant, 2016, Cardiac phenotype determines survival in Duchenne muscular dystrophy, Pediatr Pulmonol, 51, 70, 10.1002/ppul.23215 · doi:10.1002/ppul.23215
  26. Ricotti, 2016, Upper limb evaluation in Duchenne muscular dystrophy: fat-water quantification by MRI, muscle force and function define endpoints for clinical trials, PLoS One, 11, e0162542, 10.1371/journal.pone.0162542 · DOI
  27. Henricson, 2013, The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures, Muscle Nerve, 48, 55, 10.1002/mus.23808 · DOI · Paper page
  28. Vestergaard, 2001, Fracture risk in patients with muscular dystrophy and spinal muscular atrophy, J Rehabil Med, 33, 150, 10.1080/165019701750300609 · DOI
  29. Archer, 2016, Duchenne muscular dystrophy: the management of scoliosis, J Spine Surg, 2, 185, 10.21037/jss.2016.08.05 · DOI

Cited by

See all 79

Metadata

Authors
Alfano, L. N., Charleston, J. S., Connolly, A. M., Cripe, L., Donoghue, C., Dracker, R., Dworzak, J., Eliopoulos, H., Frank, D. E., Lewis, S., Lucas, K., Lynch, J., Milici, A. J., Flynt, A., Naughton, E., Rodino-Klapac, L. R., Sahenk, Z., Schnell, F. J., Young, G. D., Mendell, J. R., & Lowes, L. P.
Affiliations
  • Pediatrics, Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH
  • Sarepta Therapeutics, Inc., Cambridge, MA
  • Currently: Pediatrics, Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH
  • Summerwood Pediatrics/Infusacare Medical Services, PC, Liverpool, NY
  • Flagship Biosciences, Westminster, CO
  • PharPoint Research, Durham, NC
Venue
Medicine
Published
2019-06
Volume
98
Issue
26
Pages
e15858
ISSN
  • 0025-7974
  • 1536-5964
Cited by
79
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. https://app.cochat.ai/papers/10.1097/md.0000000000015858
The paper
Alfano, L. N., Charleston, J. S., Connolly, A. M., Cripe, L., Donoghue, C., Dracker, R., Dworzak, J., Eliopoulos, H., Frank, D. E., Lewis, S., Lucas, K., Lynch, J., Milici, A. J., Flynt, A., Naughton, E., Rodino-Klapac, L. R., Sahenk, Z., Schnell, F. J., Young, G. D., . . . Lowes, L. P. (2019). Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine. https://doi.org/10.1097/md.0000000000015858

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.